Literature DB >> 26456902

Timely disclosure of progress in long-term cancer survival: the boomerang method substantially improved estimates in a comparative study.

Hermann Brenner1, Lina Jansen2.   

Abstract

OBJECTIVE: Monitoring cancer survival is a key task of cancer registries, but timely disclosure of progress in long-term survival remains a challenge. We introduce and evaluate a novel method, denoted "boomerang method," for deriving more up-to-date estimates of long-term survival. STUDY DESIGN AND
SETTING: We applied three established methods (cohort, complete, and period analysis) and the boomerang method to derive up-to-date 10-year relative survival of patients diagnosed with common solid cancers and hematological malignancies in the United States. Using the Surveillance, Epidemiology and End Results 9 database, we compared the most up-to-date age-specific estimates that might have been obtained with the database including patients diagnosed up to 2001 with 10-year survival later observed for patients diagnosed in 1997-2001.
RESULTS: For cancers with little or no increase in survival over time, the various estimates of 10-year relative survival potentially available by the end of 2001 were generally rather similar. For malignancies with strongly increasing survival over time, including breast and prostate cancer and all hematological malignancies, the boomerang method provided estimates that were closest to later observed 10-year relative survival in 23 of the 34 groups assessed.
CONCLUSION: The boomerang method can substantially improve up-to-dateness of long-term cancer survival estimates in times of ongoing improvement in prognosis.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer registries; Methods; Period analysis; Survival

Mesh:

Year:  2015        PMID: 26456902     DOI: 10.1016/j.jclinepi.2015.09.017

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  1 in total

1.  Changes in long term survival after diagnosis with common hematologic malignancies in the early 21st century.

Authors:  Dianne Pulte; Lina Jansen; Hermann Brenner
Journal:  Blood Cancer J       Date:  2020-05-13       Impact factor: 11.037

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.